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Sickle Cell Anemia:
Current Treatments & Potential Advancements
By: Vanessa Martinez

Abstract
Sickle cell anemia is a disease that affects red blood cells, specifically the hemoglobin
protein. An amino acid mutation in the gene that encodes β-globin leads to malformation of the
β subunit of hemoglobin.3, Valine becomes glutamic acid in the mutated β-globin gene.9 The
mutation malformation leads to the red blood cells becoming sickle shaped, or crescent shaped.3,4
The sickle shape of red blood cells in individuals with sickle cell disease leads to vaso-occlusive
crisis.9 Vaso-occlusive crisis includes complications such as blood clotting, chronic pain, organ
failure, organ death, and possibly early mortality.9 The Centers for Disease Control and
Prevention reported that there are approximately 100,000 Americans who have sickle cell
disease as of their August 2016 records.21 One of every 365 African-Americans, and one in every
16,300 Hispanic-Americans have sickle cell anemia.21 There are therapies and treatments that
have already been developed based on the knowledge gained regarding the disease and its
complications. Currently, hydroxyurea therapy is the most widely accepted and used treatment
for individuals with sickle cell disease with proven relief of vaso-occlusive crisis complications.
However, with hydroxyurea therapy there are several unwanted effects that have an impact on
the patients, such as jaundice, blood clotting, and usual bleeding just to name a few.44 Studies
have noted an upregulation of the glycolytic enzyme, fructose-bisphosphate aldolase (aldolase)
in patients who have undergone hydroxyurea therapy. Aldolase is an important enzyme that
plays a role in energy conversion. With this in mind, I propose that sickle cell disease can be
treated with an increase in aldolase by myoblast treatment and/or higher fructose consumptions
thereby reducing the complications that come with the disease, as well as, drastically eliminating
the unwanted effects that come with hydroxyurea therapy.
Keywords: Sickle Cell Anemia, SCD, hemoglobin, VOC complications, aldolase, hydroxyurea
therapy, treatments, therapy
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CHAPTER ONE: SICKLE CELL ANEMIA
Introduction
Sickle cell anemia (SCA), also known as sickle cell disease (SCD), is a disease that alters
the hemoglobin in red blood cells (RBC).1 Red blood cells are commonly known to have a
circular shape. The fact that RBCs have this shape, with other unique features, make it possible
for them to travel throughout the body with ease.2 This flow of RBCs throughout the body is
what allows for oxygen, iron, chemical ions, and other important nutrients to move from one
location to another and reach their designated destination.2 In SCD, the RBC is sickled, or
crescent shaped.3, 4 These sickled cells can lead to complications known as vaso-occlusive crisis
(VOC), such blood clots, which can furthermore lead to tissue and/or organ failure. It was first
brought to the attention of the United States in the early 1900s by Dr. Herrick while he was
viewing Walter Clement Noel’s red blood cells.3, 4 Since then, there have been many contributors
to our knowledge and understanding of SCD, including Hahn and Gillespie, Dr. Neel, Nobel
prize winner Dr. Pauling, and Dr. Itano, just to name a few.3
Background
Discovery. Prior to the discovery of
sickle cell anemia in the 1900s, there was not
enough knowledge to explain the
manifestation of sickled cells. In 1910, Dr.
Herrick described unusual findings in the
blood of a young black man, of which he had
never come across before.3 Dr. Herrick was
very thorough writing his observations,
describing things such as the overall physical
features including chest deformity, redness in
the throat, enlarged glands, and several scars
up to 3 cm in diameter on his legs and
thighs; enlarged left side of the heart with a

Figure 1: Dr. Herrick's view of sickle cells4
with added contrast for enhanced
visualization
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murmur and heart rate between 64 and 100; rattling in the lungs heard throughout his chest and
back; fever that fluctuated from 99°F to 101°F; increased urine output; feces output that
contained bloody mucus; and blood descriptions, such as the shape of the red blood cells he saw
(figure 1).4 Herrick included the history of the young man named Walter Clement Noel including
that he formerly lived in Grenada, West Indies4; and addressing important associated symptoms
such as shortness of breath and palpatations3, which are defined as feeling a pounding or
fluttering heart.4 These are common features of sickle cell anemia, however, this information was
not known at that time. Also, Herrick noticed the distinct sickle shape of the red blood cells,
which is the reason for the name sickle cell anemia. A vast number of Noel’s red blood cells
were crescent-shaped, elongated, and thin.4 Dr. Herrick recognized the abnormality of the red
blood cells remained the same in all of the blood samples, regardless of how the blood was
smeared or treated, even after exposing the cells to heat, placing them in alcohol or ether
solutions, and staining them with Ehrlic stain.4 Dr. Herrick, after comparison to other healthy
individuals and looking through various aspects of Noel’s condition, could not come to a
conclusion about what the diagnosis of the patient could be. He suggested syphilis because some
of the symptoms seemed to be similar, however, no conclusion was made. Dr. Herrick ended his
article with a statement about leaving the case with an open diagnosis until more cases arose with
similar features as the young man he
observed.4 All this to say, during that
time period not too much was known
about what sickle cell anemia really
was and what caused it.
Development. Hahn and
Gillespie in 1927 discovered what
causes a red blood cell to sickle. The
red blood cells are the oxygen
transport of the body and when they
are not carrying oxygen they form the
Figure 2: Red blood cell hemoglobin protein depicted
α (bottom, pink) and β (top, orange) subunits6

crescent shape that is known as
sickle.3 Dr. James V. Neel suspected
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that sickle cell anemia was a hereditary disease in 1949. Following that suspicion, in 1951, Nobel
prize-winning chemist Dr. Linus Pauling and Dr. Harvey Itano, together made the discovery of
the chemical structure of the protein hemoglobin.3 Hemoglobin in red blood cells is a four-part
protein. These four parts consist of two pairs that encode the two protein subunits. Those two
pairs are the α-globin and the β-globin. Hemoglobin with its α-globin and β-globin subunits are
shown in Figure 2.6 Dr. Pauling and Dr. Itano discovered that hemoglobin was quite different in
those with sickle cell anemia than in healthy individuals, leading to sickle cell anemia being the
very first disease considered a molecular disease.3 In 1956, not long after the two noted the
chemical structure difference, Dr. Vernon Ingram determined the specific amino acid that led to
the restructuring of hemoglobin.
Then & Now. Due to the sickling of the red blood cells, the flow of blood within the
vascular system is very poor and can often lead to vascular restriction. Before further discoveries
and investigations on the cause of organ tissue death, vaso-occlusion seemed to be the only
reason these tissues died in patients with sickle cell disease. In more current findings, an overall
interaction between red blood cells and endothelial cells, which are cells that form the lining of
blood vessels7, plays a role in leading to dysfunction of organs. Mohandas, Hebbel, and Kaul
were the three who prompted this concept in the 20th century. As vaso-occlusion continued to be
studied by people such as Duits and Schnog, it became more evident that these vascular blocking
episodes, which occurred in people with sickle cell anemia, caused the dysfunction in the organs
differently than in healthy individuals.8, 9 Further investigation has shown a connection between
red blood cells and blood vessel walls. It is not just the shape of the red blood cell (sickle-shape),
but also the vessel wall adhesion, the way neutrophils are recruited and adhere to the cell wall
causing blockage of sickled red blood cells.8, 10
Genetics
Sickled red blood cells are noted to have only one amino acid different than normal blood
cells.3 Figure 3 shows the genes for the α-globin and β-globin subunits of hemoglobin (discussed
in background) and their locations on chromosomes 11 and 16, respectively.10, 11 The single
amino acid that gets substituted is Valine, which becomes glutamic acid.10 The year Dr. Pauling
designated sickle cell anemia as a molecular disease was the same year that it was found to
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specifically be an autosomal
recessive disease. The
severity of sickle cell anemia
is dependent on the
interaction between the αglobin and β-globin
subunits.10 When the genes
are homozygous recessive,
sickle cell anemia is at its
most severe and most
common form. However,
there are still variations of
Figure 3: Location of genes encoding α- globin and β-globin
subunits of RBC hemoglobin on chromosomes 11 and 16,
respectively.10, 11

the disease that can occur
based on how the genes
interact. Usually it is the β-

globin mutation that leads to abnormal interactions and various degrees of sickle cell disease.
When a β-globin is not produced normally, or is produced in small quantities, the gene is known
as β-thalassemia.10 The interaction between α-globin and mutated β-globin (or β-thalassemia)
subunits determines the severity of the disease. A normal α-globin and a mild mutation in βthalassemia can result in mild expression of the disease.10 Even with normal α-globin, βthalassemia in its inactive state resembles a recessive mutated β-globin and the severity of the
disease is very high, similar to an individual who has have sickle cell anemia.10
Fetal hemoglobin (HbF), with 2 γ-globin subunits, is found during fetal development and
is replaced by adult hemoglobin (HbA), with 2 β-globin subunits, as an individual gradually
develops into adulthood (figure 4).10, 11 Fetal hemoglobin becomes adult hemoglobin due to
hypomethylation by the enzyme methyltransferase, which does as its name implies, transfers
methyl groups (-CH3).12 It is not until the development of HbA and replacement of HbF is
complete that any mutations in β-globin become more phenotypically present.11 Among some
Eastern areas of Saudi Arabia and in some locations of India, lower rates of sickle cell disease
were noticed coupled with higher levels of fetal hemoglobin in adults.13, 14 In another study, low
levels of fetal hemoglobin were closely associated with increased death rates at an early age,
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50% of the
individuals died
before their fifth
decade.15 These
findings led to
future studies in
HbF and its
potential in treating
sickle cell anemia.
Demographics
Adults. As

Figure 4: Fetal hemoglobin with 2 γ-globin subunits (top hemoglobin)
before development and replacement to 2 β-globin subunits in adult
hemoglobin (bottom hemoglobin)10, 11

studies look at
sickle cell disease more closely, new findings lead to increased knowledge and understanding.
Specifically, more is known about the way proteins interact within the body on a molecular level.
Glutathione has an important part in antioxidant defense mechanisms in adults.16 Quastel,
Stewart, and Tunnicliffe confirmed glutathione was a dipeptide of cysteine and glutamic acid17
after the structure was originally proposed to be just that by Hopkins in 1921.18 This defense
system is very important because it helps control and buffer the effects of reactive oxygen
species (discussed later in chapter).19 Glutathione is now more specifically known to be
composed of glycine, glutamate, and cysteine that come together under the catalyst glutamate
cysteine ligase enzyme to form glutathione (figure 5).16, 20 The intermediate of this reaction is γ-

Figure 5: Structural formula (left) and ball-and-stick model (right) of glutathione20
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L-glutamyl-L-cysteine, which is also the rate-limiting-step in the synthesis of glutathione. On the
other hand, another reaction that can lead to the synthesis of glutathione is from a glutathione
disulfide by glutathione reductase enzyme. Glutathione is considered to be considerably low in
those who have sickle cell anemia, but the reason as to why or how the deficiency occurs is not
fully known. There seem to be factors, based on studies, that lack of sulfur amino acids
consumed in one’s diet can have an influence on the lack of glutathione that is produced.16
Another possible explanation is because individuals with sickle cell anemia have such high
oxidative stress within their bodies, then glutathione produced gets used by the body so quickly
that red blood cell count decreases because of the consumption. The latter seems to be what is
occurring on the molecular lever.16
African Decent. In 1910 when sickle cell anemia was first discovered in the United
States, the first view of sickle cells was in a young black man from the Grenada Islands in the
West Indies.5 Furthermore, sickle cell anemia has been known by other names in Africa for over
five thousand years.4 Yet, it was not until the early 1900s when the disease started to become
more clearly understood. There is commonality of the disease mostly in those from African
descent. In Jamaica, there are increased occurrences of homozygous βs disease, which is a type
of sickle hemoglobin disease.21 If the homozygous mutation of β-globin is not present, an
individual can still be considered a carrier of sickle cell disease due to the presence of mild
mutation in the gene. This particular presence of a mild mutation that does not lead to sickle cell
disease is known as having sickle cell trait.22 In many areas of Africa where malaria disease is
highly prevalent, individuals with sickle cell trait were also more prevalent and seemed to
strive.22 Malaria is a disease that causes rupturing of red blood cells due to infection of
parasites.23 Individuals with sickle cell trait, who do not have sickle cell disease, have lower
susceptibility to contracting malaria, however, the mechanism by which this occurs is not
understood.24 Although being a carrier of sickle cell trait can be beneficial against malaria, when
individuals who carry the sickle cell trait in these areas reproduce, their children are more likely
to be born with the homozygous recessive sickle cell disease and all of its complications.
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World Health Organization published data regarding the prevalence of sickle cell anemia
among various regions of the world in 2003 (Table 1).25 At that time, it was once again
confirmed that individuals of African decent have higher percentage of having sickle cell
anemia.21 The table shown also indicates that those of African descent also have higher amount
of births affected by sickle cell anemia that those in any other region of the world.25

Table 1: WHO table showing the prevalence of sickle cell anemia among various regions of
the world in 2003. Significant variant refers to sickle cell trait in which the individual
carries the gene but does not physically show symptoms, and α thalassaemia refers to the
other mild mutations that can take place. African regions have a higher percent of
individuals who are carriers of the gene over any other region. There is a much higher
affected popluation in African regions who have sickle cell anemia, 10.86 per 1,000. The
number of births affected are also much higher in African regions.25
According to the Centers for Disease Control and Prevention (CDC) August 2016
records, there are approximately 100,000 Americans who have SCD. Out of 365 AfricanAmericans, one will have the disease. Out of every 16,300 Hispanic-Americans births, one will
be diagnosed with SCD. Sickle cell trait is carried in one out of 13 African-Americans.26 This
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increases the chances of carrier parents to have offspring with sickle cell disease. Women with
sickle cell disease lived o be 42 years old in 2005. Men with sickle cell disease only lived to be
about 38 years old.27
Complications
Cardiovascular.
In regards to the
complications that sickle
cell disease bears, its
affect on one’s
cardiovascular system is
obviously one of the most
prominent. Due to the
fact that sickle cell
anemia is literally a
disease of red blood cells
makes this very evident.
Furthermore, VOC can
result in acute or chronic
pain, blood clotting,
organ failure, organ
death, and early
mortality.10 The

Figure 6: Blood clotting, vaso-occlusive crisis10

termination of blood flow due to clotting (figure 6), the lack of oxygen transport, and cell-vessel
adhesion interactions, all play a role in these VOCs.10 There is evidence that supports xanthine
oxidase is a reactive oxygen species that plays a significant role in individuals with sickle cell
anemia.28 An increase of xanthine oxidase is usually evident in the endothelium of the aorta, or is
possibly released from the liver and travels through blood vessels. Further investigations need to
be performed to come to a better understanding of the effects xanthine oxidase has on tissues of
the body, especially because not all tissues are affected in the same way.28
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Neurological. Reactive oxygen species are reduced oxygen molecules with added
electrons.29 Typically, reactive oxygen species are regulated by anti-oxidant enzymes within
individuals to ensure that one does not get harmed by inconsistencies. When these are not
regulated properly, cells begin
to dysfunction and die. Some
of the molecules that have a
role in producing reactive
oxygen species include
xanthine oxidase, NADPH
oxidase, cyclo-oxygenase,
hydroxyl radical, nitric oxide
synthase (NOS), and
lipoxygenase (examples
shown in figure 7).28, 29 Nitric
oxide synthase is the enzyme
Figure 7: Examples of some reactive oxygen species29

that catalyzes the 2-step
production of nitric oxide

from a L-arginine to L-citrulline reaction.29 Nitric oxide synthase is a reactive oxygen species
that has an affect on individuals with sickle cell anemia. Normally, NOS produces small amounts
of nitric oxide, which is used in neurons for the cascade that leads to neural transmission and
relaxation of vessels, which inhibits aggregation of platelets.30 Nitric oxide has several
pathological effects that are toxic to neurons, but are not fully understood.31, 32 Among some of
the toxic effects are energy depletion and neuron death, both of which are not fully detailed or
explained.33 More research is desired specifically in neural complications of sickle cell anemia
because not too much information is known about the details of these kinds of complications.
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CHAPTER TWO: CURRENT TREATMENTS
Introduction
There is currently no cure for sickle cell anemia because there is still more to learn about
the disease. Currently, only treatments are offered to ease the complications of sickle cell
anemia. Animal studies have been conducted to determine the role of reactive oxygen species,
endothelium adhesion, and the role of fetal hemoglobin. To date, hydroxyurea therapy is the
treatment most used and accepted for individuals with sickle cell anemia.28 And still, research is
being done on treatments that can improve the quality of life for those with the disease, as well
as, treatments that ease the complications without leading to other unwanted affects.
Animal Studies
There is evidence that reactive oxygen species play a role in individuals with sickle cell
anemia. When comparing anti-oxidant levels in normal red blood cell individuals and sickle
blood cell individuals, there is a notable difference that can be investigated.28 A study was done
by Kaul et al in 2004 on transgenic mice with sickle cell anemia looking at and measuring the
reactive oxygen species in mice with induced hypoxic crises.34 Both xanthine oxidase and
nitrotyrosine deposition are reactive oxygen species known to increase in mice with sickle cell
anemia.34 Inflammation responses in the mice were determined to be induced by nuclear factorκB (NF-κB).34, 35 NF-κB is a transcription factor that increases the transcription of endothelial
cell adhesion molecules, which are molecules that are pro-inflammatory.35 The activation of this
particular transcription factor plays a role in increased neutrophil recruitment, which was seen in
figure 5 to lead to vaso-occlusive crisis.36, 10 Kaul et al. specifically studied sulfasalazine and its
ability to treat the vaso-occlusive crisis in the transgenic sickle cell disease mice.34 Sulfasalazine
is an inhibitory agent that inactivates NF-κB in rheumatoid arthritis and inflammatory bowl
disease.37, 38 With this in mind for their study, Kaul et al. determined that sulfasalazine did
decrease neutrophil recruitment and adhesion, thus allowing for better vascular blood flow;
ultimately, being an effective anti-inflammatory drug.34 By increasing reactive oxygen species
inhibitors or anti-oxidant enzymes, artery dilations tend to be reduced and the leucocyte count
decreases as well.28 This suggests that reversing ROS is possible and can reduce vaso-occlusive
crises.

15
Anemic baboons were used to test out the effects of 5-Azacytidine on fetal hemoglobin
production.39 5-Azacytidine is a cytosine analog that cannot be methylated by a
methyltransferase.39 This molecule was used to inhibit the methylation of DNA that encodes for
β-globin. Since 5-Azacytidine inhibited this methylation, a higher number of fetal hemoglobin
was expressed in the baboons than adult hemoglobin expressed.39 This was used as a push
towards getting 5-Azacytidine tested on humans,39 however, it was not studied further due to the
fact it was thought to be carcinogenic.10 Studies were then done on hydroxyurea therapy because
it does not interfere with the methyltransferase of DNA.28, 39 This encouraged small hydroxyurea
trials on humans. Unlike 5-Azacytidine, hydroxyurea became tested on larger sample sizes to get
more understanding of its effect on sickle cell anemic organisms.10 Because of these studies,
hydroxyurea therapy has become the most utilized therapy for SCD patients.
Hydroxyurea Therapy
Hydoxyurea is a drug that has been approved by the US Food and Drug Administration
that can be used as a
therapy for sickle cell
anemia.28 This drug
therapy can
effectively reduce
sickle cell anemia
symptoms such as
vaso-occlusion,
pulmonary events, and
hospital visits, to
name a few.10, 28, 39, 40
The function of
hydroxyurea therapy
can be visualized in
figure 8.41 One of the
Figure 8: What hydroxyurea affects41 although the mechanism is not mechanisms of HU
known
induces the fetal
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hemoglobin (HbF) synthesis in SCD patients. This synthesis impairs the production of sickle cell
formation, thus extensively reducing the VOC complications.41 It was in 1984 when Letvin et al.
studied anemic monkeys and HU therapy, determining the increased production of HgF.42
Several VOCs are treated when patients undergo HU therapy. This therapy does not actually get
rid of sickle cell anemia entirely, it just helps reduce the complications that come with the
disease.10 In regards to humans, symptoms like acute chest pain, hospitalizations, painful crises,
and blood transfusions greatly declined when patients were on hydroxyurea therapy. 43 However,
it is important to note that the exact mechanism HU therapy uses is unknown. Patients who have
gone through HU therapy have experienced several unwanted effects. Some of those unwanted
effects include, but are not limited to, body aches, flu-like symptoms, easy bruising, unusual
bleeding, painful or difficult urination, confusion, hallucinations, loss of appetite, nausea, and
jaundice.44
Other Therapies
It has been proposed to induce fetal hemoglobin in individuals with sickle cell anemia to
alleviate the severity of the disease. There have been studies and observations that lead to this
therapeutic proposal. Individuals with sickle cell anemia in India and Saudi Arabia have high
amounts of fetal hemoglobin and much milder sickling. Also, fetal hemoglobin seems to prevent
sickle hemoglobin from polymerizing and causing red blood cells to sickle. Therefore, induction
of fetal hemoglobin may be a useful therapy to look further into.10 Prior to simply inducing fetal
hemoglobin, it was suggested to use 5-Azacytidine because in a small number of sickle cell
anemic patients it promoted fetal hemoglobin. Yet, bigger sample sizes were not sought after to
continue testing out this method of producing fetal hemoglobin because it was a potential
carcinogen.10
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CHAPTER THREE: ALDOLASE, POTENTIAL TREATMENT
Introduction
Currently hydroxyurea therapy is the most used and accepted treatment for individuals
with sickle cell anemia.28 This therapy is used because it helps to reduce the complications that
arise with sickle cell anemia, such as blood clotting, organ failure, and early mortality.10, 28, 39, 40
Individuals with sickle cell anemia who undergo hydroxyurea therapy have less chest pain,
hospital visits, blood transfusions, and painful vascular cirses.41 Sickle cell formation is inhibited
due to increased production of fetal hemoglobin.41 Although hydroxyurea is used for treatment, it
is not a means of curing sickle cell disease.10 The mechanism by which hydroxyurea functions is
not known and it has several unwanted affects that it is accompanied with, such as jaundice,
confusion, loss of appetite, nausea, hallucinations, and unusual bleeding just to name a few.43
After doing some research, aldolase has been found in higher amounts in individuals with sickle
cell anemia who undergo hydroxyurea therapy.45 Due to this finding, the proposal to increase
aldolase by another means is presented. Increasing aldolase without the use of hydroxyurea
therapy can both improve the quality
of life for individuals with sickle cell
anemia, as well as, rid the unwanted
affects that accompany the treatment.

Background
Fructose-bisphosphate (FBP)
aldolase is a glycosomal enzyme that
plays a major role in glycolysis. This
enzyme can be found in three
isozymic forms, defined as various
forms with the same function,
depending on the location of where it
is found. Those three forms are
aldolase A, aldolase B, and aldolase

Figure 9: 2-dimensional structure of Fructosebisphosphate aldolase49
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C. Aldolase A is most commonly found in muscle cells. Aldolase B is most commonly found in
liver cells. Lastly, aldolase C is most commonly found in the brain.46, 47 Studies have shown that
the structure of aldolase is an α/β-barrel fold.48 The structure of aldolase is shown in figure 9.49
The glycolytic function synthesizes ATP, which is the energy that can be used for more
biological processes.50 Aldolase A is defined based on its abundance in muscle tissues and its
high catalytic activity. Aldolase B is defined based on the properties it has in the liver tissue and
its low catalytic activity.51 Because aldolase is found in the cytoplasm of cells and it is soluble,
then it can be extracted by a water solution and isolated for further study.52
Studies have shown that there are increases in aldolase levels in patients who have
undergone HU therapy.45 These studies form the basis of my senior capstone proposal. From
these studies I have formed my capstone on studying a way to increase aldolase by another
means, and replace HU therapy so the patients no longer experience the unwanted effects of the
treatment.
Research Strategy
Specific Aim 1: To investigate the role aldolase plays in treatment of SCD in patients who
undergo HU.
Rationale: Studies have shown that aldolase levels increase in patients who have
undergone HU therapy.45
Approach 1: The initial step is
to measure the levels of aldolase in test
subjects to confirm the increase of
aldolase in my test subjects. My control
group will consist of 20 transgenic
mice expressing human α and βs
globins that do not undergo HU
therapy. The test group will be 20 adult
transgenic mice expressing human α
Figure 10: Example of electrophoresis50

and βs globins that undergo HU

19
therapy. Blood samples will be taken and electrophoresis will be done to check the aldolase
levels in each mouse. Figure 10 is an example of electrophoresis done to measure the enzyme
aldolase.50
Proposed Results: I expect to see higher levels of aldolase in the test group of transgenic
mice expressing human α and βs globins that undergo HU therapy.
Conclusion: Aldolase is present in higher amounts in SCD mice, which may indicate its
importance in SCD treatment.
Approach II: The next part of the approach to investigating specific aim 1 is to knock
down aldolase in mice that undergo HU therapy by transfection of cells with siRNA.
Transfection means to infect with a free nucleic acid. siRNA is considered the silencing ribose
nucleic acid. Through this method aldolase is knocked down in the transgenic mouse.53 My
control group will consist of 20 transgenic mice expressing human α and βs globins that do not
do not have aldolase blocked. The test group will be 20 adult transgenic mice expressing human
α and βs globins that do have aldolase blocked. Blood samples will be taken and electrophoresis
will be done to check the aldolase levels in each mouse. Sickle cell disease complications will be
measured and compared. The way to measure these complications is to note the complications
that each mouse encounters. There is a successful measurement when complications have been
reduced.
Proposed Results: I expect to see a greater reduction in sickle cell disease complications
in the control group of transgenic mice expressing human α and βs globins that do not have
aldolase blocked.
Conclusion: SCD complications will significantly decrease in the transgenic mice
expressing human α and βs globins that do not have the aldolase blocked. This will reinforce that
aldolase does indeed play a key role in the treatment of sickle cell disease.
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Specific Aim 2: To investigate an alternative method for increasing aldolase without using
hydroxyurea to eliminate unwanted effects.
Rationale: HU therapy has unwanted effects for patients.44
Approach I: Measure the improvement of SCD complications by increasing aldolase
through the means of myoblasts. A study was done revealing that aldolase levels increased due to
myoblasts. Myoblasts are muscle cells. This can be done by getting the mice to exercise thereby
encouraging the formation of myoblast and increasing aldolase levels. My control group will
consist of 20 transgenic mice expressing human α and βs globins that do not do not undergo the
myoblast treatment. The treatment group will be 20 adult transgenic mice expressing human α
and βs globins that do undergo the myoblast. Blood samples will be taken and electrophoresis
will be done to confirm the increased aldolase levels in each mouse. Sickle cell disease
complications will be measured and compared. The way to measure these complications is to
note the complications that each mouse encounters. There is a successful measurement when
complications have been reduced.
Proposed Results: The treatment group with 20 transgenic mice expressing human α and
βs globins that do undergo the myoblast treatment will have increased levels of aldolase and
show significant reduction of sickle cell disease complications.
Conclusion: Increasing aldolase by myoblast treatment will reduce sickle cell disease
complications and eliminate the need for HU therapy and unwanted effects.
Approach II: The second part of the approach to investigating specific aim 2 is to
measure the improvement of sickle cell disease complications by increasing aldolase through the
means of higher fructose consumption. A study was done showing that rats have increased levels
of aldolase when consuming higher amounts of fructose.54 Figure 11 shows the results of higher
aldolase levels in rats that consumed higher amounts of fructose.54 My control group will consist
of 20 transgenic mice expressing human α and βs globins that consume the normal chow. The
test group will be 20 adult transgenic mice expressing human α and βs globins that consume
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chow with 60% fructose.
Blood samples will be taken
and electrophoresis will be
done to check the aldolase
levels in each mouse. Sickle
cell disease complications
will be measured and
compared. The way to
measure these complications
Figure 11: Results indicating higher aldolase levels in rats
that consumed higher amounts of fructose54

is to note the complications
that each mouse encounters.

There is a successful measurement when complications have been reduced.
Proposed Results: The treatment group with 20 transgenic mice expressing human α and
βs globins that do consume more fructose will have increased levels of aldolase and show
significant reduction of sickle cell disease complications.
Conclusion: Increasing aldolase by higher fructose consumption will reduce sickle cell
disease complications and eliminate the need for HU therapy and unwanted effects.
Study Limitations
Some limitations of the study is that, even though we know aldolase increases in
patients who undergo HU therapy, we are not guaranteed that aldolase is specifically the
mechanism that HU therapy works by. Also, we do not know the other unwanted effects that
may come with the proposed alternative methods that will increase aldolase. It is uncertain what
the myoblast treatment or the higher fructose consumption may do to the patient. Furthermore,
because we do not know the acute effects that may come along with these methods, we also do
not know their long-term effects either.
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Significance of Study
The significance of this particular study I am proposing is finding the mechanism
that HU therapy uses to treat sickle cell disease. If this proposed study and expected results do
indeed indicate that increased levels of aldolase is the key in treatment of the disease in mice
models, then we are able to move to the next step of testing. Human patients can be recruited to
attempt these treatments and see the effectiveness they have on sickle cell disease complications.
This study will have eliminated the unwanted effects of HU therapy and helped improve patients
lives.
Future Studies
A future study can be done to investigate the limitations mentioned above. In the
future, the effects of the myoblasts treatment and high fructose consumption treatments can be
studied and monitored. In addition to investigating the effects, a study can be done looking into a
variety of dosages of the treatments. For example, instead of 60% fructose studying 80% or 50%.
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DISCUSSION
As time and technology progress more becomes known about sickle cell anemia and the
various factors that are involved in the disease. After the initial discovery of the disease in the
United States in the 1900 by Dr. Herrick, much has been discovered about the effects of sickle
cell anemia.3 Not too long after its discovery, Dr. Vernon found the amino acid that caused the
abnormality in the β-globin gene, which leads to the sickling of a red blood cell.3 Along the years
research has been done, and continues to be done, searching for a therapy or treatment for this
cardiovascular disease. Symptoms such as, organ dysfunction, hospitalization, vaso-occlusion,
and some others are the crisis that patients with sickle cell disease must deal with.10 Fortunately,
with the information that has been gained over the years about how sickling happens and how
anemia affects the body, treatments and therapies are being tested. Hydroxyurea is among the
most accepted therapies currently available with significant lessening of the complications and
symptoms sickle cell anemia patients’ have.10, 28 Further studies and investigations are being
done on other procedures and drugs that can possibly help alleviate the difficulties of this
hereditary disease.3
There is still so much to learn and investigate in regards to sickle cell anemia. Most of all,
beginning to view the organic chemistry behind the disease will help know how to directly
interact with molecules in a way to provide treatment. Reading through the information that is
already present and understanding the way that molecular interactions take place, or even being
able to see how organic chemistry plays a role in sickle cell anemia can provide a unique
perspective on further studies and therapies. Mutations, molecular interactions, oxygen-based
reductions, electrons, and so much more, allow for treatments and therapies to be specifically
aimed at providing health and comfort even with sickle cell anemia. Treatments and therapies are
already present, but still can be further investigated. Hydroxyurea is currently a favored therapy
with unwanted and unhealthy affects, but that is not to negate that there may be other options or
forms of treatment that might just be better. It simply is a matter of knowing what to look for,
knowing the molecular connections and interactions involved, addressing specific areas by
taking note of the chemistry of the molecules involved, etc. For this reason, I researched and
propose that Fructose-bisphosphate (FBP) aldolase is a better, less harming approach to treating
sickle cell anemia. Studies have already shown the increase of aldolase levels in patients who
undergo hydroxyurea therapy, but studies also show the unwanted affects that go alongside the
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treatment.44, 52 For example, jaundice, loss of appetite, body aches, and unusual bleeding, just to
name a few, are some the complications that patients who undergo HU therapy must suffer
through in order to alleviate VOC complications that come with SCD.44 If an increase in aldolase
is the mechanism by which the VOC symptoms are being relieved, then increasing aldolase by
another means rather than HU therapy will help remove these unwanted affects of the therapy.
Although aldolase cannot be a cure for SCD, based on my research, increasing aldolase can
improve the overall health and condition of those who live with sickle cell anemia.
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